Sub-Q Bionics announced it has raised $1.5 million in a pre-seed funding round to advance a novel implantable solution designed to improve care for patients living with Lymphedema. The round included participation from Mayo Clinic, Yeda Research and Development Company, several private investors, and matching support from the Israel Innovation Authority.
The company is developing a bionic lymph node technology based on scientific research from the Weizmann Institute of Science and Shamir Medical Center. The system is designed as a subcutaneous implant that enables automatic lymphatic fluid management, aiming to reduce symptoms such as swelling and pain while improving mobility and quality of life.
Lymphedema affects millions of patients globally, particularly cancer survivors, and remains underserved by existing treatment options. Sub-Q Bionics’ implantable device is intended to support lymphatic circulation beneath the skin, offering patients greater freedom of movement compared to traditional therapies.
The funding will be used to accelerate product development, advance pre-clinical milestones, and build out regulatory and commercial strategies. As part of the investment, Mayo Clinic will collaborate with the company on research and development efforts.
Sub-Q Bionics was also supported by Yeda through its Weizmann Innovation Nest venture platform, which helps translate scientific discoveries into early-stage companies and prepares them for commercialization.
The company plans to use the proceeds to further refine its technology and expects to open a seed funding round in the second quarter of 2026.
KEY QUOTES:
“Our mission at Sub-Q Bionics is to meaningfully improve the standard of care for patients living with lymphedema. This funding enables us to accelerate development of our technology and move toward critical pre-clinical milestones while building the regulatory and commercial foundation needed to ultimately serve patients.”
Jordan Pollack, CEO and Co-Founder, Sub-Q Bionics
“Sub-Q is a great example of what we aim to build at Yeda and WIN, strong ventures rooted in outstanding science and focused on real world solutions. We’re excited to support the team on their mission to build a technology that can change the lives of so many patients living with lymphatic diseases.”
Elik Chapnik, CEO, Yeda Research and Development Company
